利用RNA测序表达数据通过机器学习识别低级别胶质瘤免疫治疗靶点
本研究利用癌症基因组图谱(TCGA)中28个免疫相关基因的表达数据,构建3种机器学习模型筛选与淋巴细胞细胞溶解活性(CYT)最相关的基因,并在患者来源的胶质瘤样本中验证。ICOS、IDO1和CD40在所有模型中均为最重要变量且与CYT正相关;3例IDH突变型与3例IDH野生型样本验证显示IDH突变型胶质瘤CYT水平较低。
要点
- ICOS、IDO1和CD40在所有机器学习模型中均为与CYT最相关的重要变量。
- TIGIT和CD137也被模型列为相关变量。
- 3例IDH突变型与3例IDH野生型患者来源胶质瘤样本验证显示IDH突变型CYT水平较低。
核心结论
- 该新方法阐明了低级别胶质瘤免疫治疗开发的3个潜在靶点。
- 作者还展示了一种使用先进统计技术分析数据的新方法,可进一步用于其他疾病的治疗开发。
研究设计与样本
- 研究利用癌症基因组图谱(TCGA)生成28个与已知免疫治疗靶点或淋巴细胞细胞溶解活性相关的免疫基因表达水平。
- 研究创建训练组和测试组以及3种机器学习模型,以确定与细胞溶解活性(CYT)最相关的基因。
- 3种模型分别通过穷举选择多元回归、LASSO和随机森林运行。
- 研究通过比较患者来源胶质瘤样本中相关基因的表达来验证计算结果。
主要发现
- 模型表现出线性、低均方误差,且对最重要变量的结果一致。
- ICOS、IDO1和CD40的表达在所有模型中均为最重要变量,并与CYT呈正相关。
- 其他变量包括TIGIT和CD137。
- 来自3例IDH突变型和3例IDH野生型患者来源胶质瘤样本的遗传分析验证了TCGA数据,并显示IDH突变型胶质瘤中CYT水平低于IDH野生型。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Immunotherapy has revolutionized cancer treatment in the past decade, but significant hurdles remain. Human studies with immune checkpoint inhibitors targeting programmed cell death protein have demonstrated suboptimal efficacy in the setting of low-grade gliomas (LGGs). Identification of mechanisms leading to inadequate anti-tumor immunity is paramount. The current study evaluates and validates barriers to immunotherapy using a novel machine learning algorithm. METHODS: We utilized The Cancer Genome Atlas (TCGA) to generate expression levels of 28 immune genes related to known immunotherapeutic targets or lymphocyte cytolytic activity. We created training and testing groups and 3 machine learning models to determine the genes most highly correlated to cytolytic activity (CYT). The 3 models were run through multiple regression by exhaustive selection, LASSO, and random forest. We validated computational results by comparing expression of pertinent genes in patient-derived glioma samples. RESULTS: Our models demonstrated linearity, a low mean-squared error, and consistent results with respect to the most important variables. Expression of ICOS, IDO1, and CD40 were the most important variables in all models and demonstrated positive correlation with CYT. Other variables included TIGIT and CD137. Genetic analysis from 3 IDH-mutants (IDHm) and 3 IDH-wild type (IDHwt) patient-derived glioma samples validated TCGA data and demonstrated lower levels of CYT in IDHm gliomas compared with IDHwt. CONCLUSIONS: This novel methodology has elucidated 3 potential targets for immunotherapy development in LGGs. We also demonstrated a novel method of analyzing data using advanced statistical techniques that can be further used in developing treatments for other diseases as well.
引用
- Agarwal P, Beale OM, Zhang X, et al. Machine Learning Identification of Immunotherapy Targets in Low-Grade Glioma Using RNA Sequencing Expression Data. World Neurosurg. 2022. PMID: 35390499. doi:10.1016/j.wneu.2022.03.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。